Frequency of antineutrophil cytoplasmic antibody in Graves' disease patients treated with methimazole

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 5, 2003, Pages 2141-2146

  Gumà, Mònica ^a,b   Salinas, Isabel ^a   Reverter, Jordi L ^a   Roca, Josep ^a   Valls Roc, Marta ^a   Juan, Manel ^a   Olivé, Alejandro ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; AUTOANTIBODY; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; CATHEPSIN; ELASTASE; LACTOFERRIN; LYSOZYME; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; RADIOACTIVE IODINE; THIAMAZOLE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; IMMUNOFLUORESCENCE TEST; KAPLAN MEIER METHOD; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; SERODIAGNOSIS; TREATMENT OUTCOME;

ADULT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODY SPECIFICITY; ANTIMICROBIAL CATIONIC PEPTIDES; ANTITHYROID AGENTS; BLOOD PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GRAVES DISEASE; HUMANS; IODINE RADIOISOTOPES; MALE; MEMBRANE PROTEINS; METHIMAZOLE; MIDDLE AGED; MYELOBLASTIN; PEROXIDASE; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; SERINE ENDOPEPTIDASES;

EID: 0037692979     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-021383     Document Type: Article

References (38)

1. Savage COS, Winearls CG, Jones SJ, Marshall PD, Lockwood CM 1987 Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis. Lancet 8:1389-1393
2. Zhao MH, Lockwood CM 1996 Antineutrophil cytoplasmic autoantibodies with specificity other than PR3 and MPO (xANCA). In: Peter JB, Shoenfeld Y, eds. Autoantibodies. Amsterdam: Elsevier Science BV; 68-73
3. Font J, Ramos-Casals M, Cervera R, Bosch X, Mirapeix E; Garcia-Carrasco M, Morla RM, Ingelmo M 1998 Antineutrophil cytoplasmic antibodies in primary Sjögren's syndrome: prevalence and clinical significance. Br J Rheumatol 37: 1287-1291
4. Walmsley RS, Zhao MH, Hamilton MI, Brownlee A, Chapman P, Punder RE, Wakefield AJ, Lockwood CM 1997 Antineutrophil cytoplasm autoantibodies against BPI protein in inflammatory bowel disease. Gut 40:105-109
5. Manolova I, Dancheva M, Halacheva K 2001 Antineutrophil cytoplasmic antibodies in patients with systemic lupus erythematosus: prevalence, antigen specificity, and clinical associations. Rheumatol Int 20:197-204
6. Kitahara T, Hiromura K, Maezawa A, Ono K, Narabara N, Yano S, Naruse T, Takenouchi K, Yasumoto Y 1997 Case of propylthiouracil-induced vasculitis associated with anti-neutrophil cytoplasmic antibody (ANCA); review of literature. Clin Nephrol 47:336-340
7. Gunton JE, Stiel J, Caterson RJ, McElduff A 1999 Anti-thyroid drugs antineutrophil cytoplasmic antibody-positive vasculitis. A case report and review of the literature. J Clin Endocrinol Metab 84:13-16
8. Pillinger M, Staud R 1998 Wegener's granulomatosis in a patient receiving propylthiouracil for Graves' disease. Semin Arthritis Rheum 28:124-129
9. Noh JY, Asari T, Hamada N, Makino F, Ishikawa N, Abe Y, Ito K 2001 Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves' disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations. Clin Endocrinol (Oxf) 54:651-654
10. Sera N, Ashizawa K, Ando T, Abe Y, Ide A, Usa T, Tominaga T, Ejima E, Yokohama N, Eguchi K 2000 Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease. Thyroid 10:595-599
11. Sato H, Hattori M, Fujieda M, Sugihara S, Inomata H, Hoshi M, Miyamoto S 2000 High prevalence of antineutrophil cytoplasmic antibody positivity in childhood-onset Graves' disease treated with propylthiouracil. J Clin Endocrinol Metab 85:4270-4273
12. Hori Y, Arizono K, Hara S, Kawai R, Hara M, Yamada A 1996 Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis associated with thiamazole therapy. Nephron 74:734-735
13. D'Cruz D, Chesser AM, Lightowler C, Comer M, Hurst MJ, Baker LR, Raine AE 1995 Antineutrophil cytoplasmic antibody-positive crescentic glomerulo-nephritis associated with anti-thyroid drug treatment. Br J Rheumatol 34: 1090-1091
14. Tsai MH, Chang YL, Wu VC, Chang CC, Huang TS 2001 Methimazole-induced pulmonary hemorrhage associated with antimyeloperoxidase-antineutrophil cytoplasmic antibody: a case report. J Formos Med Assoc 100: 772-775
15. Afeltra A, Paggi A, De Rosa FG, Manfredini P, Addessi MA, Amoroso A 1998 Antineutrophil cytoplasmic antibodies in autoimmune thyroid disorders. Endocr Res 24:185-194
16. Wiik A 1989 Delineation of a standard procedure for indirect immunofluorescence detection of ANCA. APMIS Suppl 6:12-13
17. Kaplan EL, Meier P 1958 Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
18. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG 1977 Design and analysis of randomized clinical trials requiring prolonged observation of each patient II; analysis and examples. Br J Cancer 35:1-39
19. Hagen EC, Daha MR, Hermans J, Andrassy K, Csemok E, Gaskin G, Lesaure P, Ludemann J, Rasmussen N, Sinico RA, Wiik A, Van der Woude FJ 1988 Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 53:743-753
20. Gumà M, Olive A, Juan M, Salinas I 2002 ANCA antibodies in Graves' disease. Ann Rheum Dis 61:90-91
21. Hagen EC, Andrassy K, Csernok E, Daha MR, Gaskin G, Gross WL, Hansen B, Heigl Z, Hermans J, Jayne D, Kallenberg CG, Lesavre P, Lockwood CM, Ludemann J, Mascart-Lemone F, Mirapeix E, Pusey CD, Rasmussen N, Sinico RA, Tzioufas A, Wieslander J, Wiik A, Van der Woude FJ 1996 Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. J Immunol Methods 196:1-15
22. McLaren JS, Stimson RH, McRorie ER, Coia JE, Luqmani RA 2001 The diagnostic value of anti-neutrophil cytoplasmic antibody testing in a routine clinical setting. Q J Med 94:615-621
23. Morita S, Arima T, Matsuda M 1995 Prevalence of nonthyroid specific autoantibodies in autoimmune thyroid diseases. J Clin Endocrinol Metab 80: 1203-1206
24. Petri M, Karlson EW, Cooper DS, Ladenson PW 1991 Autoantibody tests in autoimmune thyroid disease: a case-control study. J Rheumatol 18:1529-1531
25. Ynamo Y, Harada K 1997 Antinuclear antibody positivity in pediatric patients with autoimmune thyroid disease. J Rheumatol 24:576-578
26. Loviselli A, Velluzzi F, Pala R, Marcello A, Nurchis P, Mathieu A, Bartalena L, Martina E, Grasso L 1992 Circulating antibodies to DNA-related antigens in patients with autoimmune thyroid disorders. Autoimmunity 14:33-36
27. Armengol MP, Juan M, Lucas-Martin A, Fernández-Figueras MT, Jaraquemada D, Gallart T, Pujol-Borrell R 2001 Demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers. Am J Pathol 159:861-873
28. Coutelier JP, Kehrl JH, Bellur SS, Kohn LD, Notkins AL, Prabhakar BS 1990 Binding and functional effects of thyroid-stimulating hormone on human immune cells. J Clin Immunol 10:204-210
29. Balázs C, Bokk A, Kiss E 1992 Inhibition of metabolic activity of polymorphonuclear granulocytes by thyroid stimulating antibodies. J Endocrinol Invest 15:465-469
30. Kiss E, Balázs C, Bene L, Damjanovich S, Matkó J 1997 Effect of TSH and anti-TSH receptor antibodies on the plasma membrane potential of polymophonuclear granulocytes. Immunol Lett 55:173-177
31. Weetman AP, McGregor AM, Hall R 1984 Evidence for an effect of antithyroid drugs on the natural history of Graves' disease. Clin Endocrinol (Oxf) 21:163-172
32. Volpe R 1994 Evidence that the immunosuppressive effects of antithyroid drugs are mediated through actions on the thyroid cell, modulating thyrocyte-immunocyte signaling: a review. Thyroid 4:217-223
33. Kim H, Lee TH, Hwang YS, Bang MA, Kim KH, Suh JM, Chung HK, Yu DY, Lee KK, Kwon OY, Ro HK, Shong M 2001 Methimazole as an antioxidant and immunomodulator in thyroid cells: mechanisms involving interferon γ signaling and H202 scavenging. Mol Pharmacol 60:972-980
34. Zhao MH, Jones SJ, Lockwood CM 1995 Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis. Clin Exp Immunol 99:49-56
35. Cooper T, Savige J, Nassis L, Paspaliaris B, Neeson P, Neil J, Knight KR, Daskalabis M, Doery JC 2000 Clinical associations and characterization of antineutrophil cytoplasmic antibodies direct against bactericidal/permeability-increasing protein and azurocidin. Rheumatol Int 19:129-136
36. Nishiya K, Chikazawa H, Nishimura S, Hisakawa N, Hashimoto K 1997 Anti-neutrophil cytoplasmic antibody in patients with systemic lupus erythematosus is unrelated to clinical features. Clin Rheumatol 16:70-75
37. Roozendaal C, Van Milligen de Wit AW, Haagsma EB, Horst G, Schwarze C, Peter HH 1998 Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: defined specificities may be associated with distinct clinical features. Am J Med 105:393-399
38. Mahadeva R, Dunn AC, Westerbeek RC, Sharpies L, Whitehouse DB, Carroll NR, Ross-Russell RI, Webb AK, Bilton D, Lomas DA, Lockwood CM 1999 Anti-neutrophil cytoplasmic antibodies (ANCA) against bactericidal/permeability-increasing protein (BPI) and cystic fibrosis lung disease. Clin Exp Immunol 117:561-567